Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of IMC-1121B plus modified FOLFOX-6 in first-line metastatic colorectal cancer
2008-004936-19Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Nov 2008; status: completed.
02
Drugs
ramucirumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-004936-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004936-19.